Fight Severe Coronavirus with This Arthritis Drug?! [One New Study]

The fastest way to come up with a treatment for COVID-19 isn’t to develop a new one… it’s to find one that already exists.

Many drugs have seemed promising—like hydroxychloroquine and remdesivir—only to disappoint in the end.

But researchers have just identified a drug helped turn the tide for some critically ill patients with COVID-19.

You’ll want to show this study to your doctor.

Arthritis drugs are a go-to for researchers because they treat an overreactive immune response in the body. And severe COVID-19 infections are also characterized by an overactive response that stirs up something called a cytokine storm.

Unfortunately, most of these drugs have not been effective against COVID-19… until now.

In one new study, researchers identified a drug that can possibly help save the lives of patients with severe cases of COVID-19.

It’s called tocilizumab, and it’s an immune-modulator used to treat rheumatoid arthritis drugs. Researchers started testing it on COVID-19 patients because of its ability to calm overactive immune responses in the body.

This was a large-scale clinical trial that tracked 4,000 critically ill COVID-19 patients from 67 hospitals across the US.

The results showed that while 37 percent of COVID-19 patients admitted to the ICU died, “just” 27 percent of those treated with tocilizumab died.

Smaller studies showed mixed results, which highlights why large-scale studies like this one are so important.

Here’s the important part: For the best results, tocilizumab had to be given within three days of developing symptoms.

Tocilizumab is typically only given once, through an IV, although a second dose can be given if necessary.

If you develop COVID-19, you want to arm your body with every defense possible for the best possible outcome.

Tocilizumab could be one of the most important tools in that arsenal.